Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy
| Autor: | Birgitte Rahbek Kornum, Steen Gammeltoft, Lars Østergaard Pedersen, Anja Holm, Poul Jennum, Justyna M.C. Bahl, Signe Modvig, Karina Fog |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Neurofilament light Central nervous system tau Proteins Idiopathic Hypersomnia CHI3L1 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid Neurofilament Proteins Physiology (medical) Internal medicine mental disorders Total Tau Protein medicine Humans In patient Chitinase-3-Like Protein 1 Narcolepsy Orexins Amyloid beta-Peptides business.industry Neurodegeneration Neurodegenerative Diseases medicine.disease 030104 developmental biology medicine.anatomical_structure Endocrinology Case-Control Studies alpha-Synuclein Female Neurology (clinical) business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | ResearcherID |
| ISSN: | 1550-9109 |
| DOI: | 10.1093/sleep/zsw006 |
| Popis: | Objectives To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration. Methods Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1). Results Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals. Conclusion Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|